LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Search

PerkinElmer Inc

Gesloten

SectorGezondheidszorg

0

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Belangrijke statistieken

By Trading Economics

Inkomsten

-8.6M

47M

Verkoop

-21M

699M

K/W

Sectorgemiddelde

47.923

77.256

EPS

1.18

Dividendrendement

0.3

Winstmarge

6.675

Werknemers

11,000

EBITDA

-14M

181M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+24.11% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.30%

2.33%

Volgende Ex Dividend datum

16 jan 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-486M

11B

Vorige openingsprijs

0

Vorige sluitingsprijs

0

Nieuwssentiment

By Acuity

21%

79%

44 / 374 Rangschikking in Healthcare

PerkinElmer Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 nov 2025, 21:06 UTC

Belangrijke Marktbewegers

JBS Down After Trump Calls for Probe into Meat-Packing Companies

7 nov 2025, 22:36 UTC

Winsten

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7 nov 2025, 22:22 UTC

Winsten

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7 nov 2025, 22:03 UTC

Winsten

Constellation Software 3Q Rev $2.95B >CSU.T

7 nov 2025, 22:03 UTC

Winsten

Constellation Software 3Q Net $210M >CSU.T

7 nov 2025, 22:03 UTC

Winsten

Constellation Software 3Q EPS $9.89 >CSU.T

7 nov 2025, 21:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

7 nov 2025, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

7 nov 2025, 20:59 UTC

Winsten

Palantir's CEO Says His Earnings Were the Best Ever. They Weren't Even the Best of the Week. -- Barrons.com

7 nov 2025, 20:26 UTC

Marktinformatie

Natural U.S. Gas Futures Extend Rally to Three Weeks -- Market Talk

7 nov 2025, 20:22 UTC

Winsten

Free-Spending Big Tech Dominates Earnings. As for the Rest: Don't Miss. -- Barrons.com

7 nov 2025, 20:04 UTC

Marktinformatie

Oil Futures Close Choppy Week With Losses -- Market Talk

7 nov 2025, 19:34 UTC

Marktinformatie

Gold Posts Small Gain for Week -- Market Talk

7 nov 2025, 19:31 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Prices of Gas-Fired Power Plants Have Room to Grow -- Market Talk

7 nov 2025, 19:17 UTC

Winsten

These Stocks Are Moving the Most Today: Tesla, Expedia, Take-Two, Block, Affirm, Sunrun, Globus Medical, JFrog, and More -- Barrons.com

7 nov 2025, 19:09 UTC

Winsten

Wendy's Turnaround Won't Be Easy. Earnings, and the Stock, Tell the Story. -- Barrons.com

7 nov 2025, 19:08 UTC

Winsten

KKR Defied Private-Equity Fundraising Slump in the Third Quarter -- WSJ

7 nov 2025, 18:31 UTC

Marktinformatie

U.S. Oil RIg Count Unchanged at 414 -- Market Talk

7 nov 2025, 17:27 UTC

Marktinformatie

EPA Announces New Exemptions to Biofuel Blending Rules -- Market Talk

7 nov 2025, 17:20 UTC

Marktinformatie

Eli Lilly GLP-1 Deal with Trump Administration Provides Net Boost -- Market Talk

7 nov 2025, 17:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

7 nov 2025, 17:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

7 nov 2025, 17:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

7 nov 2025, 17:17 UTC

Acquisities, Fusies, Overnames

Satair Expects to Complete Purchase in Early 2026

7 nov 2025, 17:17 UTC

Acquisities, Fusies, Overnames

Satair: Deal Includes Unical's and ecube's Seven Operational Sites and Offices, With Combined 2024 Rev of $298M and Headcount of 413

7 nov 2025, 17:15 UTC

Acquisities, Fusies, Overnames

Airbus Unit Satair to Buy Unical Aviation From Platinum Equity

7 nov 2025, 17:09 UTC

Marktinformatie

PENN Is Falling Further Behind Competitors -- Market Talk

7 nov 2025, 16:49 UTC

Marktinformatie

Losing ESPN Partnership Will Hurt PENN -- Market Talk

7 nov 2025, 16:24 UTC

Marktinformatie

OPEC+'s Output Hike Pause Comes Amid Excess Supply, Lower Spare Capacity -- Market Talk

7 nov 2025, 16:17 UTC

Marktinformatie

Oil Market Faces Oversupply But "Glut" Might Be Overblown -- Market Talk

Peer Vergelijking

Prijswijziging

PerkinElmer Inc Prognose

Koersdoel

By TipRanks

24.11% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 111.1 USD  24.11%

Hoogste 125 USD

Laagste 100 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor PerkinElmer Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

11 ratings

8

Buy

3

Hold

0

Sell

Sentiment

By Acuity

44 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat